CLARITY PHARMACEUTICALS Mediaroom

Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range

Highlights * Clarity recently reported that in its diagnostic Phase 1/2 trial, COBRA, 64 Cu-SAR-b...

2024-03-08 22:02 1637

Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range

Registrational Phase III CLARIFY trial in prostate cancer commences

SYDNEY, Nov. 30, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical st...

2023-11-30 22:16 1191

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level

HIGHLIGHTS * Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the ...

2023-11-30 21:59 1306

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level

Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort

HIGHLIGHTS * Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67 Cu-SAR-bisPSMA in met...

2023-11-29 21:58 1219

Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial

SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical sta...

2023-11-07 21:58 1042

Clarity and PSI kick off SAR-bisPSMA Phase III

SYDNEY, Oct. 26, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical st...

2023-10-26 21:00 1132

First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial

SYDNEY, Oct. 3, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-sta...

2023-10-03 20:58 1631

First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

Highlights * First participant of cohort 3 in the theranostic SECuRE trial investigating 64Cu/67...

2023-08-25 20:58 2485

First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

Clarity's theranostic prostate cancer trial advances to highest dose level

Highlights * Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in met...

2023-08-10 20:58 2184

Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial

SYDNEY, July 24, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company")...

2023-07-24 21:02 1615

Positive guidance from US FDA on Cu-64 SAR-bisPSMA Phase III trial in prostate cancer

Highlights * FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in pros...

2023-07-04 20:55 2109

Clarity establishes a US Center of Excellence for Targeted Copper Theranostics

SYDNEY, June 28, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-st...

2023-06-28 20:58 2021

Clarity commences COMBAT theranostic prostate cancer trial in the US

SYDNEY, June 20, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical st...

2023-06-20 21:03 1810

Clarity's theranostic prostate cancer trial advances to cohort 2

Highlights * Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic c...

2023-05-24 21:03 2498

Clarity's theranostic prostate cancer trial advances to cohort 2

US based COBRA diagnostic prostate cancer trial reaches recruitment target

SYDNEY, Feb. 9, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-sta...

2023-02-09 22:03 2103

IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer

SYDNEY, Nov. 21, 2022 /PRNewswire/ -- Highlights * Clarity's fifth successful Investigational N...

2022-11-21 22:04 3414

First patient treated in Clarity's therapeutic prostate cancer trial

Highlights * Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic ph...

2022-10-07 21:06 1628

Recruitment opens for Phase II trial in prostate cancer with Cu-64 SAR-Bombesin in the US

SYDNEY, Sept. 5, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical st...

2022-09-05 21:09 2520

Clarity advances to cohort 3 of the CL04 trial of SARTATE™ in paediatric neuroblastoma

Highlights * Cohort 2 completed in participants with neuroblastoma who received therapy with67Cu...

2022-08-23 21:04 2649

Recruitment complete for Clarity's PROPELLER prostate cancer diagnostic trial

SYDNEY, July 20, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-st...

2022-07-20 21:06 1201

Latest News